GIA
DERM icon

Gladstone Institutional Advisory’s Journey Medical DERM Stock Holding History

Gladstone Institutional Advisory’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$125K Sell
26,571
-2,500
-9% -$19.4K ﹤0.01% 814
2025
Q4 		$224K Buy
29,071
+500
+2% +$3.92K 0.01% 721
2025
Q3 		$203K Sell
28,571
-4,283
-13% -$31.1K 0.01% 754
2025
Q2 		$236K Sell
32,854
-4,000
-11% -$27.6K 0.01% 665
2025
Q1 		$217K Buy
36,854
+6,873
+23% +$33.8K 0.01% 671
2024
Q4 		$117K Sell
29,981
-3,500
-10% -$19.1K 0.01% 682
2024
Q3 		$189K Hold
33,481
– – 0.01% 662
2024
Q2 		$189K Buy
+33,481
New +$138K 0.01% 629

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gladstone Institutional Advisory's DERM Position: Q1 2026 in Review

Gladstone Institutional Advisory reduced its Journey Medical (DERM) stake by 8.6% in Q1 2026, selling an estimated $19.4K and leaving 26,571 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #814.

Gladstone Institutional Advisory first reported a position in DERM in Q2 2024 and has held it in 8 quarters since. The position peaked at $236K in Q2 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q1 2026.

  • Gladstone Institutional Advisory held 26,571 shares of Journey Medical worth $125K as of Q1 2026.
  • Gladstone Institutional Advisory sold 2,500 Journey Medical shares in Q1 2026, an estimated $19.4K.
  • Journey Medical made up ﹤0.01% of Gladstone Institutional Advisory's portfolio in Q1 2026, its #814 holding.
  • Gladstone Institutional Advisory first reported a position in Journey Medical in Q2 2024 and has held it in 8 quarters since.
  • Gladstone Institutional Advisory's Journey Medical position peaked at $236K in Q2 2025.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q1 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q1 2026, filed 14 May 2026.